High Risk Breast MRI Screening
Currently, dynamic contrast enhanced breast magnetic resonance imaging (DCE-MRI) is the most sensitive imaging method for breast cancer detection. DCE-MRI relies on the contrast enhancement characteristics of breast cancer relative to the background breast parenchyma. Numerous studies have shown DCE-MRI to be superior to mammography and ultrasound in identifying breast cancer at a significantly earlier stage in high-risk screening populations (12, 20, 21) . Not only does screening with breast MRI result in a higher sensitivity (71-100%) than mammography (13%-59%) and ultrasound (13%-65%), a significant number of MRI detected cancers (43%) are less than 1 cm in size when compared with those detected by mammography and ultrasound ( p<0.001) (12, (20) (21) (22) . Furthermore, the sensitivity of MRI in detecting these additional cancers is unaffected by the age of the patient, their breast density, or their genetic mutation status (23) .
Magnetic resonance imaging-detected breast cancers have the advantage of being less frequently associated with axillary nodal metastases (21.4%) when compared with mammography detected cancers (54.6% p<0.001) (12) . The improved performance of MRI over traditional screening modalities translates into improved overall survival in patients with BRCA1 and 2 mutations. Evans et al. (24) used the prospective magnetic resonance imaging breast screening study (MARIBS) patient survival data on 649 women aged 35-55 years who received annual MRI screening based on the presence of a proven or likely BRCA1, BRCA2, or TP53 mutation in addition to 338 patients who underwent screening MRI after the implementation of the National Institute for Health and Care Guidance (NICE) criteria endorsing MRI screening. Ten-year overall survival (OS) rate for patients screened with MRI in addition to mammography was 95.3% compared to 87.7% in patients screened with mammography alone. In light of compelling evidence that supports MRI's superior sensitivity, the American College of Radiology (ACR) and the American Cancer Society (ACS) currently recommend intensive imaging screening with DCE-MRI for women with BRCA 1 and BRCA 2 mutations or women at a greater than 20% lifetime risk for the development of breast cancer using computer-based risk assessment models (25, 26) .
Magnetic resonance imaging is a highly technical and expensive imaging modality, traditionally requiring multiple pulse sequences for diagnostic evaluation. The acquisition and table times required for standard DCE-MRI protocols range between 20-60 minutes (27) and are a limiting factor in the population-based use of DCE-MRI for breast cancer screening. Women who refused breast MRI screening as part of the American College of Radiology Imaging Network (ACRIN) 6666 trial reported that the long scan times required and the claustrophobia of the magnet bore itself were reasons for their refusal to undergo a breast MRI as a supplemental breast cancer screening tool (15, 28) .
The Concept of Abbreviated Breast MRI
Similar to the paradigm of screening and diagnostic mammography, some have proposed that a stripped-down, shortened contrast-enhanced MRI protocol containing the minimum number of sequences required for the detection of suspicious enhancing lesions (abbreviated MRI, or AB-MRI) might be sufficient for breast cancer screening, with a full diagnostic MRI protocol reserved for the characterization and differentiation of benign from malignant disease (29) . In 2014, Kuhl et al. (30) reported a retrospective reader study in which a full diagnostic DCE-MRI consisting of 8 different pulse sequences was obtained on a cohort of 443 women with a mildly elevated risk of breast cancer or dense breast tissue. Separate interpretations of the complete DCE-MRI and a subset of images containing only the unenhanced images and the first post contrast dynamic sequence had equivalent diagnostic accuracy and negative predictive value for detecting breast cancer. AB-MRI had a very high cancer yield: using the AB-MRI images only, 11 cancers were detected, resulting in a cancer detection rate of 18.1 per 1000. Four of the cancers were ductal carcinoma in situ (DCIS), and seven were invasive cancers. All of the invasive cancers were less than 1.0 cm in size, and there were no axillary metastases identified clinically or at sentinel lymph node biopsy. The specificity and positive predictive value of AB-MRI was equivalent to the full DCE-MRI (94.3% versus 93.9% and 24.8% versus 23.4%) (30) . The negative predictive value of the AB-MRI was 99.8%. The mean acquisition time was three minutes for the AB-MRI versus 17 minutes for the full DCE-MRI, with a reading time of less than 30 seconds for the abbreviated protocol. Other retrospective reader studies have reported similar results (31-33).
The AB-MRI protocol reported by Kuhl did not include a T2 weighted series as required by the ACR for accreditation of breast MRI, nor did it include the full dynamic series of post contrast images. While the European Society of Breast Imaging recommends either a pre-contrast T1 weighted or T2 weighted series be obtained (34) , both societies require that a full dynamic series before and after the administration of contrast be obtained. The full dynamic sequence allows the use of computer aided detection and time-intensity-curves that help differentiate benign from malignant enhancing lesions (35, 36) (Figure 1 ). The T2 weighted sequence allows for the differentiation of benign, enhancing, fat containing masses such as fibroadenomas, intramammary lymph nodes, and fat necrosis from malignant enhancing masses ( Figure 2 ). Thus, while obtaining a full dynamic sequence and a T2-weighted series may increase the overall scan time by 4-6 minutes, the advantage is being able to have all the signals (fat, water, and contrast) available should a cancer be detected, and pre-operative lesion extent derived from MR images be required, without having to perform a second dedicated diagnostic scan.
In 2018 Dogan et al. (27) reported the development of an AB-MRI protocol consisting of a single T2-weighted series combined with a dynamic contrast-enhanced T1-weighted series before and after the administration of intravenous contrast. This protocol used Dixon based imaging for fat suppression with both series, where T2-weighted images were acquired using a fast spin echo (FSE) triple echo Dixon sequence (37) and T1-weighted images were acquired using a dual-echo fast spoiled gradient echo (FSPGR) sequence (38) . The Dixon method acquires two or more echoes after a single radiofrequency (RF) excitation, followed by advanced reconstruction algorithms to achieve uniform fat/water separation. This method generates both a water-only (i.e. fat-suppressed) image and a fat-only image, which can be subsequently combined to reconstruct the in-phase (i.e. non-fat-suppressed) image in a single acquisition (39) , and is well-suited for the AB-MRI protocol. In contrast to the traditional methods of fat suppression using chemically-selective fat saturation, Dixon-based methods achieve uniform fat suppression even in the presence of B0 inhomogeneities (40) , which are commonly encountered in breast MRI (41) . Large abbreviated MRI series using differing protocols are compared in Table 1 .
The flexibility of Dixon acquisitions make this approach compatible with both T1-weighted gradient echo (GRE) based acquisitions (38) and T2-weighted FSE based acquisitions (37) . By combining the advantages of fast scanning of FSE with the efficient fat/water separation of the Dixon method into a single scan, significantly shorter scan times (1-1.5 minutes) were realized for T2-weighted imaging (37, 38, 42) . Since this approach also generates T2-weighted images with and without fat suppression in a single acquisition, this eliminates the necessity of additional T2-weighted acquisitions, significantly decreasing the total scan times. Similarly, the use of dual-echo FSPGR for DCE-MRI generates T1-weighted images with and without fat suppression in a single acquisition. In addition to providing uniform fat suppression, this approach also eliminates the necessity of subtracting post-contrast images from the pre-contrast image, thus minimizing motion artifacts. In Dogan's study, the AB-MRI incorporating T2-weighted FSE-Dixon and T1-weighted FSPGR-Dixon, required a mean acquisition time of 9.4 minutes with a total table time of 13.92 minutes which was statistically significantly different (p<0.0001) than the 22 minute mean acquisition time and the 35.87 minute total table time required by the traditional DCE-MRI (27) .
The use of Dixon sequences with AB-MRI allows for both T2-and T1-weighted images with and without fat suppression, which are then used for reading. Since these provide all the signal and anatomical information of a conventional DCE-MRI protocol, these image sets can be accessed by the reader on an as needed basis for the further evaluation of enhancing lesions, thereby obviating the need for the patient to return for an additional "diagnostic" MRI for further evaluation.
In addition to decreasing MRI scan time to almost the same as mammography acquisition time, there is evidence that AB-MRI can provide image quality benefits (43) . Standard DCE-MRI and AB-MRI were compared in a reader study for adequacy of fat saturation, degree of fat saturation, presence and severity of artifact, and the image quality of normal anatomic structures (nipple, fibro-glandular tissue, lymph nodes, and chest wall) (27) . Compared to the DCE-MRI protocol, the AB-MRI protocol had statistically significant less motion artifact (p<0.0001) and better fat saturation (p=0.004). The reduced motion artifact was attributable to the much shorter scan time in which patient motion is reduced. The fat saturation was most improved in the posterior aspect of the breast allowing for better evaluation of the chest wall and axillary lymph nodes. There was no significant difference regarding lesion type, lesion margin, or enhancement pattern between the standard DCE-MRI and the AB-MRI, and the final BIRADS assessment of each was identical (27) .
AB-MRI in Average Risk Women
If AB-MRI protocols are adopted successfully, AB-MRI for screening may become more widely available to women at average or mildly elevated risk for the development of breast cancer, such as women with dense breast tissue or those with a personal history of breast cancer (44) . In a study of AB-MRI in a cohort of women at average risk for the development of breast cancer, with no evidence of cancer with traditional screening methods, Kuhl et al. (45) found an unexpectedly high cancer detection rate of 15.1 per 1000 women screened. Like the cancers detected in high risk women, the majority were small, T1 invasive cancers and over 90% were node negative. The cancers detected were of intermediate (39%) or high histologic grade (43%) with one third of cancers being of the triple negative subtype. The positive predictive value (PPV) of the AB-MRI was 35.7% well within the range of PPV accepted for mammographic screening (25-40%). Additionally, the interval cancer rate in women undergoing several rounds of screening with AB-MRI was zero. After conclusion of the study, when the women returned to traditional breast cancer screening methods, no cancers were detected by mammography or ultrasound within the first three years.
In the United States, contrast-enhanced breast MRI current procedural terminology (CPT) code is currently the same independent of the time required for the examination. However, decreasing scan time can potentially have a downstream effect of driving down the AB-MRI cost to the patient. Furthermore, finding aggressive breast cancers at an earlier stage would decrease the severity and cost of treatment, resulting in further cost savings. Furthermore, the fact that patients had no mammography or ultrasound-detected cancer for three years after screening MRI in the study by Kuhl et al. (45) suggests that AB-MRI screening may have a "protective" effect on subsequent breast cancer detection so that the frequency of screening might be reduced in average risk women, another significant cost saving.
AB-MRI for Screening Women with Dense Breast Tissue--The EA1141 Trial
The effect of breast density legislation in the United States has prompted the evaluation of supplemental screening methods for breast cancer detection in women with dense breast tissue who are without other breast cancer related risk factors. "Comparison of AB-MRI and DBT in Breast Cancer Screening in Women with Dense Breasts", the EA-1141 Trial, is a prospective multicenter trial of the ECOG/ACRIN. Women ages 40-75 with dense breast tissue (BIRADS C or D) but not at increased risk of breast cancer will undergo DBT and AB-MRI in randomized order for two consecutive years. Metrics assessed will be the cancer detection rate (CDR) of the two modalities as well as the histopathological profiles of cancers detected by the two imaging methods. The study will also assess patient reported quality of life as well as their willingness to undergo repeated breast MRI for breast cancer screening. The trial leaves the specific sequences of the abbreviated protocol up to the individual centers and only requires that the scans be obtained in less than ten minutes. Patient accrual has been completed and results are expected within the next year.
AB-MRI in Women with a Personal History of Breast Cancer
Abbreviated breast MRI has more recently been shown to be of benefit for women with a personal history of breast cancer but no other breast cancer risk factors. Choi et al. (46) reported the outcomes of AB-MRI in a cohort of 725 women with a personal history of breast cancer. AB-MRI detected 12 cancers in 12 women (CDR 15 per 1000 women screened). At the time of AB-MRI screening there was no evidence of malignancy with previously performed mammography or ultrasound. The sensitivity of the AB-MRI was 100% and the specificity was 89.2%. All AB-MRI detected cancers except one were node negative, T1 invasive cancers, or DCIS. These outcomes are comparable to outcomes reported in other series of women with a personal history of breast cancer, but who underwent a full DCE-MRI (47, 48) .
Conclusion
Abbreviated breast MRI consisting of a single T2 weighted fast spin echo (FSE) triple echo Dixon sequence and a dual echo fast spoiled gradient echo sequence (FSPGR) before and after the administration of contrast, compliant with ACR standards for the accreditation of breast MRI, with sensitivity for breast cancer detection equivalent to full protocol DCE-MRI, but with greatly reduced scan and table times, is feasible. While cancers detected with AB-MRI are usually small T1, node negative invasive cancers, they often have aggressive histopathological tumor profiles. Given its superior performance and the greatly reduced scan times resulting from the use of abbreviated protocols, AB-MRI has the potential to replace mammography as a stand-alone imaging tool for the detection of breast cancer, not only in high risk women, but in women of average or mildly elevated risk, such as women with dense breast tissue or a personal history of breast cancer. 
